To evaluate the impact of GPT2‐dominated glutamate metabolism in therapy for chronic lung inflammation, we selected a transaminase inhibitor AOA to target glutamate metabolism and reduce glutamate conversion to α‐KG and assessed the therapeutic effects of AOA in the preclinical model of COPD. The gene discussed is GPT2; the disease is chronic obstructive pulmonary disease.